AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Biceltis 440mg Injection

Prescription Icon
Prescription Required

Marketer

Cipla Ltd

Salt Composition

Trastuzumab (440mg)

Overview Biceltis 440mg Injection

Oncaspar 440mg Injection is indicated for treating breast and gastric cancers. Its mechanism involves targeting and destroying cancerous cells by suppressing HER2 (human epidermal growth factor receptor 2). Administration is via injection by a qualified healthcare provider. Dosage and frequency are determined by your physician based on your condition and may be adjusted. Strictly adhere to your doctor's instructions; incorrect usage or overdose may lead to severe adverse reactions. Therapeutic benefits may not be immediately apparent, potentially taking weeks or months; discontinue only under medical supervision. Common side effects include nausea, headache, skin rash, sleep disturbances, and infections. This medication can lower blood cell counts (red and white), increasing infection risk. Regular blood tests are crucial to monitor blood cell levels, along with heart, liver function, and uric acid. Report shortness of breath, cough, chills, or limb swelling to your doctor immediately. Inform your healthcare team of all other medications you are taking, as interactions are possible. Use during pregnancy or breastfeeding is contraindicated. Effective contraception is essential for both partners throughout treatment. A patient support program exists in India, facilitated by Tata 1mg; contact your physician or call (1800-102-1618) for more information.

Primary Ingredients of Biceltis 440mg Injection

No information provided. Please provide the text you wish to be rewritten.

Uses of Biceltis 440mg Injection

Cancers of the breast and stomach

Major Benefits of Biceltis 440mg Injection:

This medication will be administered by your physician or registered nurse; self-medication is strictly prohibited.

Common Side effects of Biceltis 440mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Biceltis 440mg Injection:

Administering this medication will be handled by your healthcare provider. Self-medication is strongly discouraged.

How Biceltis 440mg Injection works:

The injectable drug Biceltis 440mg, a recombinant IgG1 monoclonal antibody, targets HER2 receptors—human epidermal growth factor receptor proteins—that fuel uncontrolled cell growth in breast and gastric cancers. Its mechanism involves neutralizing HER2, thereby halting cancerous proliferation and disrupting associated downstream signaling cascades.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concurrent use of Biceltis 440mg Injection and alcohol can lead to increased sleepiness.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Biceltis 440mg Injection during pregnancy poses a confirmed risk to fetal development and is therefore contraindicated. In exceptional, life-threatening circumstances, a physician might consider its use only when the potential advantages outweigh the inherent dangers. Physician consultation is essential.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administration of Biceltis 440mg Injection while breastfeeding is likely inadvisable. Scant evidence from human studies indicates potential transfer of the medication into breast milk, posing a risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The effect of Biceltis 440mg Injection on driving ability is undetermined. Refrain from operating a vehicle if you experience symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

The use of Biceltis 440mg Injection in patients with kidney impairment is likely safe. Existing evidence indicates dose modification may not be necessary, however, physician consultation is recommended.

LiverLiverCONSULT YOUR DOCTOR

Data regarding Biceltis 440mg Injection use in individuals with hepatic impairment is scarce. Physician consultation is advised.

What if you forget to take Biceltis 440mg Injection :

Omitting a scheduled dose of Biceltis 440mg Injection necessitates contacting your physician.

Facts to Know About Biceltis 440mg Injection

LabelValue
Chemical Type Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Medications
Action Class Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Biceltis 440mg Injection

Biceltis 440mg Injection may cause side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, and unusual bleeding or bruising. Other possible side effects are stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea or vomiting, appetite loss, rapid heartbeat, discolored or decreased urine output, painful urination, and other signs of infection. Contact your doctor immediately if you experience any of these symptoms.
Women of childbearing age must use reliable contraception throughout Biceltis 440mg Injection therapy and for seven months afterward. Pregnancy planning can resume seven months post-treatment.
Early-stage breast cancer patients should receive Biceltis 440mg Injection for one year, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Biceltis 440mg Injection does not require fasting. Administration must be supervised by a physician experienced in cancer chemotherapy and performed only by a qualified healthcare professional.
Biceltis 440mg Injection is available in two formulations: intravenous (IV) infusion and subcutaneous (SC) injection. Always verify the product label to administer the prescribed formulation. The IV formulation is for intravenous use only; it must not be given subcutaneously. Your doctor can change your treatment between IV and SC Biceltis 440mg Injection as needed.
Biceltis 440mg Injection, a monoclonal antibody, targets the HER2 protein found on some cancer cells. Its mechanism of action involves binding to HER2, inhibiting cancer growth and spread. Consequently, this injection is only effective in patients with HER2-positive cancer and is not indicated for those with HER2-negative disease.
Using Biceltis 440mg Injection with anthracyclines (like doxorubicin) can harm your heart. Your doctor must assess your heart health before and throughout treatment.
Cardiac evaluations are necessary at treatment initiation, every three months during treatment, and every six months post-treatment for 24 months following the final Biceltis 440mg Injection. Patients with pre-existing cardiac conditions require evaluations every twelve weeks.
Biceltis 440mg Injection
49,578
MRP 54,650
9% off